Literature DB >> 19420173

Development and assessment of a multiplex real-time PCR assay for quantification of human immunodeficiency virus type 1 DNA.

A Beloukas1, D Paraskevis, C Haida, V Sypsa, A Hatzakis.   

Abstract

Previous studies showed that high levels of human immunodeficiency virus type 1 (HIV-1) DNA are associated with a faster progression to AIDS, an increased risk of death, and a higher risk of HIV RNA rebound in patients on highly active antiretroviral therapy. Our objective was to develop and assess a highly sensitive real-time multiplex PCR assay for the quantification of HIV-1 DNA (RTMP-HIV) based on molecular beacons. HIV-1 DNA quantification was carried out by RTMP in a LightCycler 2.0 apparatus. HIV-1 DNA was quantified in parallel with CCR5 as a reference gene, and reported values are numbers of HIV-1 DNA copies/10(6) peripheral blood mononuclear cells (PBMCs). The clinical sensitivity of the assay was assessed for 115 newly diagnosed HIV-1-infected individuals. The analytical sensitivity was estimated to be 12.5 copies of HIV-1 DNA per 10(6) PBMCs, while the clinical sensitivity was 100%, with levels ranging from 1.23 to 4.25 log(10) HIV-1 DNA copies/10(6) PBMCs. In conclusion, we developed and assessed a new RTMP-HIV assay based on molecular beacons, using a LightCycler 2.0 instrument. This multiplex assay has comparable sensitivity, reproducibility, and accuracy to single real-time PCR assays.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19420173      PMCID: PMC2708521          DOI: 10.1128/JCM.01264-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  37 in total

1.  T cell receptor excision circles and HIV-1 2-LTR episomal DNA to predict AIDS in patients not receiving effective therapy.

Authors:  J J Goedert; T R O'Brien; A Hatzakis; L G Kostrikis
Journal:  AIDS       Date:  2001-11-23       Impact factor: 4.177

2.  PCR-Based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells.

Authors:  C Christopherson; Y Kidane; B Conway; J Krowka; H Sheppard; S Kwok
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Molecular beacons: probes that fluoresce upon hybridization.

Authors:  S Tyagi; F R Kramer
Journal:  Nat Biotechnol       Date:  1996-03       Impact factor: 54.908

4.  Real time quantitative PCR.

Authors:  C A Heid; J Stevens; K J Livak; P M Williams
Journal:  Genome Res       Date:  1996-10       Impact factor: 9.043

5.  Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.

Authors:  Scott M Hammer; Michael S Saag; Mauro Schechter; Julio S G Montaner; Robert T Schooley; Donna M Jacobsen; Melanie A Thompson; Charles C J Carpenter; Margaret A Fischl; Brian G Gazzard; Jose M Gatell; Martin S Hirsch; David A Katzenstein; Douglas D Richman; Stefano Vella; Patrick G Yeni; Paul A Volberding
Journal:  Top HIV Med       Date:  2006 Aug-Sep

6.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

7.  Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy.

Authors:  Angelos E Hatzakis; Giota Touloumi; Nikos Pantazis; Cleo G Anastassopoulou; Olga Katsarou; Anastasia Karafoulidou; James J Goedert; Leondios G Kostrikis
Journal:  AIDS       Date:  2004-11-19       Impact factor: 4.177

8.  Quantitative detection of human immunodeficiency virus type 1 (HIV-1) viral load by SYBR green real-time RT-PCR technique in HIV-1 seropositive patients.

Authors:  Davide Gibellini; Francesca Vitone; Elisa Gori; Michele La Placa; Maria Carla Re
Journal:  J Virol Methods       Date:  2004-02       Impact factor: 2.014

9.  The use of fluorescent molecular beacons in real time PCR of IgH gene rearrangements for quantitative evaluation of multiple myeloma.

Authors:  J Martínez-López; J J Lahuerta; P Salama; R Ayala; J M Bautista
Journal:  Clin Lab Haematol       Date:  2004-02

10.  Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.

Authors:  Bruno Hoen; David A Cooper; Fiona C Lampe; Luc Perrin; Nathan Clumeck; Andrew N Phillips; Li-Ean Goh; Stefan Lindback; Daniel Sereni; Brian Gazzard; Julio Montaner; Hans-Jurgen Stellbrink; Adriano Lazzarin; Diane Ponscarme; Shlomo Staszewski; Lars Mathiesen; Don Smith; Robert Finlayson; Rainer Weber; Laurence Wegmann; George Janossy; Sabine Kinloch-de Loes
Journal:  Clin Infect Dis       Date:  2007-06-26       Impact factor: 9.079

View more
  5 in total

Review 1.  Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.

Authors:  Véronique Avettand-Fènoël; Laurent Hocqueloux; Jade Ghosn; Antoine Cheret; Pierre Frange; Adeline Melard; Jean-Paul Viard; Christine Rouzioux
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

2.  Rapid turnover of 2-LTR HIV-1 DNA during early stage of highly active antiretroviral therapy.

Authors:  Weijun Zhu; Yanmei Jiao; Rongyue Lei; Wei Hua; Rui Wang; Yunxia Ji; Zhiying Liu; Feili Wei; Tong Zhang; Xuanlin Shi; Hao Wu; Linqi Zhang
Journal:  PLoS One       Date:  2011-06-08       Impact factor: 3.240

3.  The Use of Ultra-Sensitive Molecular Assays in HIV Cure-Related Research.

Authors:  Catherine Kibirige
Journal:  J AIDS Clin Res       Date:  2013-05-27

Review 4.  Measuring the Success of HIV-1 Cure Strategies.

Authors:  Jordan Thomas; Alessandra Ruggiero; William A Paxton; Georgios Pollakis
Journal:  Front Cell Infect Microbiol       Date:  2020-04-07       Impact factor: 5.293

Review 5.  Quantification of Total HIV DNA as a Marker to Measure Viral Reservoir: Methods and Potential Implications for Clinical Practice.

Authors:  Simone Belmonti; Simona Di Giambenedetto; Francesca Lombardi
Journal:  Diagnostics (Basel)       Date:  2021-12-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.